Butler Hospital Trials Diranersen for Early Alzheimer Disease
Diranersen, an investigational antisense oligonucleotide therapy, lowered tau protein production and showed signs of cognitive benefit in early Alzheimer disease during the phase 2 CELIA study, according to a recent clinical trial evaluation. Butler Hospital’s Memory and Aging Program participated as a clinical trial site for the research, helping assess the treatment’s safety and biomarker effects over a 76-week period.
CELIA Study Design and Dosing Protocol
The trial enrolled more than 400 individuals diagnosed with mild cognitive impairment due to Alzheimer disease or mild Alzheimer disease dementia. Participants received one of three intrathecal doses of diranersen or a placebo administered over 76 weeks. Researchers at sites around the world evaluated the therapy for safety, tolerability, biomarker changes, and clinical outcomes.
#GAPNet site Butler Hospital @MemoryAndAging was a part of the team of research centers that studied Tauvid, the new FDA-approved drug that helps identify Tau protein tangles – a hallmark of #Alzheimers https://t.co/dUHcKqAsW7#ABAM #AlzheimersAndBrainAwarenessMonth
Diranersen is engineered as a tau-targeting antisense oligonucleotide designed to reduce the production of the tau protein. Tau pathology is a key feature of Alzheimer disease associated with disease progression.
Leadership and Institutional Commitment
Stephen Salloway, founding director of the Memory and Aging Program at Butler Hospital, served on the study steering committee to guide the clinical trial. Salloway stated that the findings represent progress in the search for treatments that may help slow progression of Alzheimer disease.
Mary Marran, president and chief operating officer at Butler Hospital, noted that the facility’s involvement reflects the hospital’s commitment to research and expanding access to clinical trials for people with neurological diseases.
Frequently Asked Questions About the Trial
What is diranersen and how does it work?
Diranersen is an investigational tau-targeting antisense oligonucleotide therapy designed to reduce the production of the tau protein, which is associated with disease progression.
Who was eligible to participate in the CELIA study?
The study enrolled more than 400 participants with mild cognitive impairment due to Alzheimer disease or mild Alzheimer disease dementia.
How long did participants receive the treatment?
Participants received one of three intrathecal doses of diranersen or a placebo over 76 weeks.